Sen. Ron Wyden (D-OR) (Francis Chung/E&E News/POLITICO via AP Images)

The pol­i­tics be­hind drug short­ages: Sen­a­tors talk is­sues with gener­ics mar­ket, CMS pay­ments

The gener­ic drug mar­ket took cen­ter stage Tues­day at a Sen­ate Fi­nance Com­mit­tee hear­ing on drug short­ages as law­mak­ers on Capi­tol Hill work to rem­e­dy some dire sit­u­a­tions for crit­i­cal med­i­cines.

The hear­ing comes as the US is in the thick of sev­er­al se­vere short­ages for com­mon­ly used drugs, in­clud­ing can­cer drugs, AD­HD meds and an­tibi­otics.

Sen­ate Fi­nance Chair Ron Wyden (D-OR) blamed a com­bi­na­tion of “mar­ket fail­ures” for dri­ving on­go­ing short­ages, point­ing to is­sues with gener­ics man­u­fac­tur­ing and phar­ma­cy ben­e­fit man­agers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA